These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9672 related articles for article (PubMed ID: 1954344)

  • 1. Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
    Byers VS; Baldwin RW
    Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
    Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
    Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
    Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
    Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
    Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
    Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
    Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
    Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
    [No Abstract]   [Full Text] [Related]  

  • 8. Specific ex-vivo depletion of human bone marrow T lymphocytes by an anti-pan-T cell (CD5) ricin A-chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplantation; 1987 Mar; 43(3):421-6. PubMed ID: 3103275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
    Neville DM
    Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
    Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE
    Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
    Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
    JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor bone marrow treatment with T101 Fab fragment-ricin A-chain immunotoxin prevents graft-versus-host disease.
    Laurent G; Maraninchi D; Gluckman E; Vernant JP; Derocq JM; Gaspard MH; Rio B; Michalet M; Reiffers J; Dreyfus F
    Bone Marrow Transplant; 1989 Jul; 4(4):367-71. PubMed ID: 2789084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS; O'Day S; Nadler LM; Grossbard ML
    Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic use of immunotoxins.
    Cobb PW; LeMaistre CF
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxins containing ricin or its A chain.
    Vitetta ES; Thorpe PE
    Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
    Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW
    Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
    Byers VS; Henslee PJ; Kernan NA; Blazar BR; Gingrich R; Phillips GL; LeMaistre CF; Gilliland G; Antin JH; Martin P
    Blood; 1990 Apr; 75(7):1426-32. PubMed ID: 2180494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
    Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
    Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 484.